Area of research
Cardiology and Cardiovascular Medicine · Internal Medicine
Research interest
Research interests include Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, Blood Coagulation and Thrombosis Mechanisms, and Cardiac Arrhythmias and Treatments.
Varicose vein surgery after acute isolated superficial vein thrombosis in daily practice: INSIGHTS-SVT study
Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial
Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease
Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment